^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
...for the treatment of advanced CRC include sunitinib plus FOLFIRI, cetuximab plus brivanib, erlotinib plus bevacizumab, cediranib plus FOLFOX/CAPEOX, and atezolizumab plus cobimetinib. These regimens are not recommended for the treatment of patients with CRC.
